Efficacy and safety of 0.05% cyclosporine ophthalmic emulsion in treatment of Chinese patients with moderate to severe dry eye disease: A 12-week, multicenter, randomized, double-masked, placebo-controlled phase III clinical study

scientific article published on 01 August 2019

Efficacy and safety of 0.05% cyclosporine ophthalmic emulsion in treatment of Chinese patients with moderate to severe dry eye disease: A 12-week, multicenter, randomized, double-masked, placebo-controlled phase III clinical study is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1097/MD.0000000000016710
P932PMC publication ID6709181
P698PubMed publication ID31374063

P2093author name stringWei Chen
Di Chen
Jing Hong
Mingchang Zhang
Yan Shao
Shunhua Zhang
Jialiang Zhao
Ailing Bian
Yingping Deng
P2860cites workAssociation between symptoms and signs of dry eye among an elderly Chinese population in Taiwan: the Shihpai Eye StudyQ28246849
Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporin A.Q31775977
Grading Of Corneal and Conjunctival Staining in the Context of Other Dry Eye TestsQ35542950
Sensitivity and reliability of objective image analysis compared to subjective grading of bulbar hyperaemiaQ36172041
The Ocular Redness Index: a novel automated method for measuring ocular injectionQ37037763
Efficacy and Safety of Topical 0.05% Cyclosporine Eye Drops in the Treatment of Dry Eye Syndrome: A Systematic Review and Meta-analysisQ38516740
TFOS DEWS II Clinical Trial Design ReportQ38652975
TFOS DEWS II Diagnostic Methodology reportQ38652978
TFOS DEWS II pathophysiology reportQ38652987
TFOS DEWS II Tear Film Report.Q38652990
TFOS DEWS II Epidemiology ReportQ38652994
Clinical utility of cyclosporine (CsA) ophthalmic emulsion 0.05% for symptomatic relief in people with chronic dry eye: a review of the literatureQ39151688
Prevalence of dry eye among adult Chinese in the Beijing Eye StudyQ39836983
Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study GroupQ41730611
A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trialQ42941533
Prevalence of dry eye disease in Mongolians at high altitude in China: the Henan eye studyQ42966054
Topical cyclosporine 0.05% for the prevention of dry eye disease progressionQ43087530
Blood concentrations of cyclosporin a during long-term treatment with cyclosporin a ophthalmic emulsions in patients with moderate to severe dry eye diseaseQ44206861
The lack of association between signs and symptoms in patients with dry eye diseaseQ45122466
Prevalence and risk factors associated with dry eye syndrome among senior high school students in a county of Shandong Province, ChinaQ45129629
Topical cyclosporine inhibits conjunctival epithelial apoptosis in experimental murine keratoconjunctivitis siccaQ45190856
Improving the topical ocular pharmacokinetics of lyophilized cyclosporine A-loaded micelles: formulation, in vitro and in vivo studies.Q52598288
Evaluation of Reliability and Validity of Three Common Dry Eye Questionnaires in ChineseQ58700419
Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytesQ73180482
Reliability and validity of the Ocular Surface Disease IndexQ73801624
Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporineQ77729873
P433issue31
P921main subjecteye diseaseQ3041498
placeboQ269829
cyclosporineQ367700
P304page(s)e16710
P577publication date2019-08-01
P1433published inMedicine (Barcelona) / Programa de Educación Médica Continuada (EMC) en medicina AsistencialQ29044007
P1476titleEfficacy and safety of 0.05% cyclosporine ophthalmic emulsion in treatment of Chinese patients with moderate to severe dry eye disease: A 12-week, multicenter, randomized, double-masked, placebo-controlled phase III clinical study
P478volume98

Search more.